Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape.
Pankaj SharmaXiaolong ZhangKevin LyJi Hyung KimQi WanJessica KimMumeng LouLisa KainLuc TeytonFlorian WinauPublished in: Science (New York, N.Y.) (2024)
Tumors develop strategies to evade immunity by suppressing antigen presentation. In this work, we show that prosaposin (pSAP) drives CD8 T cell-mediated tumor immunity and that its hyperglycosylation in tumor dendritic cells (DCs) leads to cancer immune escape. We found that lysosomal pSAP and its single-saposin cognates mediated disintegration of tumor cell-derived apoptotic bodies to facilitate presentation of membrane-associated antigen and T cell activation. In the tumor microenvironment, transforming growth factor-β (TGF-β) induced hyperglycosylation of pSAP and its subsequent secretion, which ultimately caused depletion of lysosomal saposins. pSAP hyperglycosylation was also observed in tumor-associated DCs from melanoma patients, and reconstitution with pSAP rescued activation of tumor-infiltrating T cells. Targeting DCs with recombinant pSAP triggered tumor protection and enhanced immune checkpoint therapy. Our studies demonstrate a critical function of pSAP in tumor immunity and may support its role in immunotherapy.
Keyphrases
- dendritic cells
- transforming growth factor
- immune response
- epithelial mesenchymal transition
- end stage renal disease
- cell death
- oxidative stress
- bone marrow
- peritoneal dialysis
- mesenchymal stem cells
- prognostic factors
- patient reported outcomes
- drug induced
- lymph node metastasis
- patient reported
- smoking cessation
- high glucose
- replacement therapy
- diabetic rats